These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15183629)

  • 21. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model.
    Zago V; Lucero D; Macri EV; Cacciagiú L; Gamba CA; Miksztowicz V; Berg G; Wikinski R; Friedman S; Schreier L
    Ann Nutr Metab; 2010; 56(3):198-206. PubMed ID: 20203480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age related changes in the antilipolytic effects of nicotinic acid in rat adipose tissue.
    Caparrotta L; Fassina G; Gaion RM; Tessari F
    Br J Pharmacol; 1983 Dec; 80(4):663-70. PubMed ID: 6571225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triglycerides, fatty acids and insulin resistance--hyperinsulinemia.
    Kraegen EW; Cooney GJ; Ye J; Thompson AL
    Exp Clin Endocrinol Diabetes; 2001; 109(4):S516-26. PubMed ID: 11453039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of AY-25,712 on fatty acid metabolism in rats.
    Cayen MN; Kallai-Sanfacon MA; Dubuc J; Greselin E; Dvornik D
    Atherosclerosis; 1982 Dec; 45(3):281-90. PubMed ID: 7159499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adipose tissue as a buffer for daily lipid flux.
    Frayn KN
    Diabetologia; 2002 Sep; 45(9):1201-10. PubMed ID: 12242452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
    Pike NB
    J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
    Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
    J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small-molecule compounds that modulate lipolysis in adipose tissue: targeting strategies and molecular classes.
    Wang M; Fotsch C
    Chem Biol; 2006 Oct; 13(10):1019-27. PubMed ID: 17052606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of hormone-stimulated lipolysis by clofibrate. A possible mechanism for its hypolipidemic action.
    D'Costa MA; Angel A
    J Clin Invest; 1975 Jan; 55(1):138-48. PubMed ID: 162783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body fat distribution, insulin mediated suppression of non-esterified fatty acids and plasma triglycerides in obese subjects.
    Herranz L; Zapata A; Grande C; Megia A; Pallardo LF
    Horm Metab Res; 1998 Mar; 30(3):141-5. PubMed ID: 9566856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antilipolytic and lipolytic effects of administering free or ruminally protected nicotinic acid to feed-restricted Holstein cows.
    Pescara JB; Pires JA; Grummer RR
    J Dairy Sci; 2010 Nov; 93(11):5385-96. PubMed ID: 20965354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
    Linke A; Sonnabend M; Fasshauer M; Höllriegel R; Schuler G; Niebauer J; Stumvoll M; Blüher M
    Atherosclerosis; 2009 Jul; 205(1):207-13. PubMed ID: 19131065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
    Taggart AK; Kero J; Gan X; Cai TQ; Cheng K; Ippolito M; Ren N; Kaplan R; Wu K; Wu TJ; Jin L; Liaw C; Chen R; Richman J; Connolly D; Offermanns S; Wright SD; Waters MG
    J Biol Chem; 2005 Jul; 280(29):26649-52. PubMed ID: 15929991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.
    Semple G; Skinner PJ; Gharbaoui T; Shin YJ; Jung JK; Cherrier MC; Webb PJ; Tamura SY; Boatman PD; Sage CR; Schrader TO; Chen R; Colletti SL; Tata JR; Waters MG; Cheng K; Taggart AK; Cai TQ; Carballo-Jane E; Behan DP; Connolly DT; Richman JG
    J Med Chem; 2008 Aug; 51(16):5101-8. PubMed ID: 18665582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.
    Dobbins RL; Shearn SP; Byerly RL; Gao FF; Mahar KM; Napolitano A; Nachbaur GJ; Le Monnier de Gouville AC
    Diabetes Obes Metab; 2013 Nov; 15(11):1013-21. PubMed ID: 23701262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of substrate utilization, manipulated by nicotinic acid, on excess postexercise oxygen consumption.
    Trost S; Wilcox A; Gillis D
    Int J Sports Med; 1997 Feb; 18(2):83-8. PubMed ID: 9081262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A.
    Zhang Y; Schmidt RJ; Foxworthy P; Emkey R; Oler JK; Large TH; Wang H; Su EW; Mosior MK; Eacho PI; Cao G
    Biochem Biophys Res Commun; 2005 Aug; 334(2):729-32. PubMed ID: 16018973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
    Tang H; Lu JY; Zheng X; Yang Y; Reagan JD
    Biochem Biophys Res Commun; 2008 Oct; 375(4):562-5. PubMed ID: 18722346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.